Oxford Vacmedix licences its novel diagnostic test for Anti Microbial Resistance to Changzhou Biotech for Greater China Oxford, UK – 11th April 2024 Press Release – OVM licences AMR diagnostic to CBI Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today the grant of a licence for its novel diagnostic test […]
Oxford Vacmedix licences AMR diagnostic to Changzhou Biotech Read More »
FGK Clinical Research GmbH, announces the successful acquisition of Clinicology Ltd. This strategic move marks a significant milestone for both companies and benefits OVM Oxford, UK – 4th March 2024 Press Release – Sale of Clinicology Ltd. Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today that Clinicology Ltd, the contract
The team at Oxford Vacmedix contribute to the design and the delivery of a novel MSc course in Applied Cancer Science being run by the Department of Oncology at the University of Oxford Oxford, UK – 26th February 2024 Press Release – Oxford Vacmedix support new University of Oxford educational initiative Oxford Vacmedix (OVM), the
Oxford Vacmedix team support new University of Oxford educational initiative Read More »
OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable three years post manufacture – a major milestone for OVM’s lead cancer vaccine, OVM-200 Oxford, UK – 31st January 2024 Press Release – OVM-200 major milestone three year stabilty Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today
Oxford Vacmedix announces major milestone in clinical development of OVM-200 Read More »
Ongoing discussions at an advanced stage with leading shareholder DxVx, to license OVM-200 for South Korea and for China. Oxford, UK – 28th November 2023 Press Release – Licensing deal with Dx&Vx for OVM-200 in South Korea and China Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today ongoing licensing
Licensing deal with Dx&Vx for OVM-200 in South Korea and China Read More »
A new publication in Advanced Therapeutics comprehensively reviews the rationale and preclinical results for OVM-200 both alone and in combination. Oxford, UK – 10th October 2023 Press Release – Importance of Survivin as a target and potential for combination use to treat cancer Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of
Oxford Vacmedix to feature in ITN Business’ programme ‘Advancing Immunology’ – exploring the use of new technology to develop vaccines to treat cancer Oxford, UK – 26th May 2023 ITN Business present Oxford Vacmedix in a new series on ‘Advancing Immunology’. The programme explores how cancer therapeutic vaccines are being trialled and could reduce the
Oxford Vacmedix feature in ‘Advancing Immunology’ Read More »
OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable two years post manufacture – a major milestone for OVM’s lead cancer vaccine development Oxford, UK – 12th May 2023 Press Release – Oxford Vacmedix announces major manufacturing milestone for OVM-200 Oxford Vacmedix (OVM), the UK-based biopharma company developing therapeutic cancer vaccines,
Oxford Vacmedix announces major manufacturing milestone for OVM-200 Read More »
New appointment In Professor Shisong Jiang’s research group in the Department of Oncology brings further expertise to research applications for Recombinant Overlapping Peptides (ROPs) Oxford, UK – 5th April 2023 Press Release – Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of
Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford Read More »
The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed – the first clinical trial of a cancer vaccine using novel ROP technology. Oxford, UK – 29th March 2023 Press Release – Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200